Bank fund, Corporate investor, Fundraising, Institutional investor, Seed funding, Venture capital, Biotech, Cancer therapeutics, Cleantech, Diagnostics, Drug Delivery, Drug Discovery, Food tech, Genomics, Immunology, Medical Device, Neurosciences, Oncology, Personalised medicine, Therapeutics, Business strategy, IP & Licensing, Market access, Startups, Technology transfer
my website http://www.scientex.eu/ will give you a very good overview of my background. *
Tim MULLER, pharma PhD + MS finance + MS management, founded SCIENTEX in 2006 : After a first R&D experience on radiopharmaceuticals at AREVA R&D (CEA) in 1993, Tim worked as a R&D pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabetes mellitus & CNS; moved in 1999 to the private equity industry (CDC enterprises & Sofimac Partners) investing in 17 healthcare private companies (8 were acquired by industrials & 5 IPOs) from his 600 deal flow proactively sourced. In 2006, Tim founded SCIENTEX in order to act as a transition manager in business & corporate development, M&A (both buy & sell side) for healthcare SMEs, while he was advising wealthy individuals on VIX trading & working with primary & secondary private equity funds.
After +26 missions, Tim joined CROSSJECT in 2012 at its restart in order to transform its medtech business model presenting a 2M€ valuation into an Euronext listed specialty pharma (IPO in feb 14 valued 65M€). Tim, acting as CBO & member of the executive board, negotiated a 472M$ ww R&D partnering deal on ZENEO epinephrin; while he was leading & driving the $6M refinancing closed in june 2013. While managing M&A opportunities, Tim initiated & engaged the IPO process, successfully oversubscribed 4,4 x in feb 2014 & negotiated 2 out-licensing deals for ZENEO MTX covering China valuated 360M€ including 25% royalties & covering indian regions including royalties between 20% to 40%. Globally, Tim has been involved in +100 corporate & business transactions, on sell & buy side, including 5 IPOs, 9 M&A, 8 out-licensing deals, 29 commercial deals, 28 venture deals with a worldwide coverage. To date, Tim has been board member for 26 companies.